Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Since the Novo Nordisk (CSE: NOVOb) share price peaked in June last year just above the DKK 1,000 mark, it has suffered a severe setback and has now fallen by over 40%. In Decembe ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

The Michael Almereyda and Courtney Stephens movie, narrated by Chloë Sevigny and premiering at the Rotterdam film festival, explores the life of the utopian neuroscientist who developed the isolation ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.